EVAX EVAX
Company Profile ↓Company Overview
EVAX (EVAX) is a publicly traded company listed on with a market capitalization of $1.24B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $7.53M (+125.1% YoY); net profit $-7.71M.
- Trailing 12 Months Year-on-year growth — revenue +125.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 125.12% |
Stock Price Performance
| 1 Year: | +9.56% |
| 6 Months: | -6.58% |
| 3 Months: | -32.27% |
| 1 Month: | -9.97% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.57 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 72.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 37.00K | 7.49M | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 3.87M | 4.38M | 4.47M | 4.05M | 3.82M |
| Operating Income | -3.87M | -4.34M | 3.02M | -4.05M | -3.82M |
| EBITDA | -1.38M | -4.79M | 5.71M | -8.29M | -3.51M |
| Interest Expense | 397.00K | 241.00K | 1.36M | -2.11M | 332.00K |
| Pretax Income | -1.77M | -5.03M | 4.35M | -6.17M | -3.85M |
| Tax Provision | -192.00K | -195.00K | -265.00K | -256.00K | -216.00K |
| Net Income | -1.58M | -4.83M | 4.62M | -5.92M | -3.63M |
| Diluted EPS | -0.50 | -1.00 | 0.50 | -1.00 | -0.50 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 73.00K | 3.34M | 7.53M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 25.26M | 22.27M | 18.08M | 16.76M |
| Operating Income | -25.26M | -22.20M | -14.73M | -9.23M |
| EBITDA | -22.57M | -21.40M | -9.79M | -7.12M |
| Interest Expense | 798.00K | 897.00K | 962.00K | 876.00K |
| Pretax Income | -23.94M | -22.91M | -11.36M | -8.62M |
| Tax Provision | -772.00K | -790.00K | -788.00K | -908.00K |
| Net Income | -23.17M | -22.12M | -10.57M | -7.71M |
| Diluted EPS | -49.00 | -40.50 | -10.00 | -1.00 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 22.02M | 12.89M | 12.48M | 28.41M |
| Current Assets | - | 16.98M | 8.35M | 8.77M | 24.90M |
| Cash & Equivalents | - | 13.18M | 4.18M | 5.95M | 23.23M |
| Inventory | - | - | - | - | - |
| Receivables | - | 1.31M | 1.07M | 1.86M | 1.05M |
| Total Liabilities | - | 13.72M | 17.62M | 14.14M | 11.37M |
| Current Liabilities | - | 3.76M | 7.08M | 4.37M | 4.26M |
| Long Term Debt | - | 7.86M | 8.49M | 8.01M | 5.35M |
| Total Debt | - | 10.26M | 10.87M | 10.10M | 7.50M |
| Total Equity | - | 8.30M | -4.73M | -1.65M | 17.04M |
| Shares Outstanding | - | 24.14M | 37.90M | 70.13M | 417.01M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -25.77M | -17.69M | -12.94M | -6.62M |
| Investing Cash Flow | - | -268.00K | -93.00K | -3.00K | -14.00K |
| Financing Cash Flow | - | 7.85M | 10.69M | 13.13M | 22.41M |
| Capital Expenditure | -1.36M | -292.00K | -87.00K | - | -11.00K |
| Free Cash Flow | - | -26.07M | -17.78M | -12.94M | -6.64M |
| Net Change in Cash | - | -18.19M | -7.09M | 186.00K | 15.77M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | -30,406.8% | -440.6% | -122.7% |
| Net Margin % | - | -30,308.2% | -316.0% | -102.4% |
| ROE % | -279.0% | 467.9% | 639.6% | -45.2% |
| ROCE % | -138.3% | -382.4% | -181.5% | -38.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EVAX
Evaxion Biotech A/s Stock Price Forecast. Should You Buy EVAX? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE5GWER6TXRNUFVBY3JIY3ZsMllrakFQM1FoaUxjQU5tMVBCRndaT2Nib2RlUlVlX1k1ZHMwY3lxOEJncGYzODQzWA?oc=5" target="_blank">Evaxion Biotech A/s Stock Price Forecast. Should You Buy EVAX?</a>&nb…
Evaxion A/S Revenue Breakdown – NASDAQ:EVAX - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE0xcWVLb3E3OTRETUFUbHZjYTByUERsWnptQkRQRnF3R3JQQlZSeUowZ0dkZm1WY1REWXpjaV9uUlc4ajlkTTZJRFJ1Wl9BeDE4TjVHem16dmhVT1otSW5POEpTSExTMjBZd2I1bjNzX19PazczVVlv?oc=5" target="_blank">Evaxion…
Evaxion to post Q1 results before market open, webcast at 8:30 ET - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOQUl1Si1vRkdfVW9ZTVNUcnoybzhGY1M1by1KYmZRMFZ0elo2akl1UzhCMUtBRUI1aDMxbG1rckl3NV9ObmxydFRKcGpKRzdneUY1Y2tCaUNJMWd3a29zSUpkcjRsRThOU3dHUHN0WFh0bnB2clB5R2s0Y3A0em5rNzVGX1QtOHBrXzliVW…
EVAX|Evaxion Biotech A/S|Price:2.780|Chg%:-0.040 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFA1Q3pzUTY3NkFtSHR4Uy1MWnpkX3dIOXBYa2xzSUlldEpidGk1Q1JCQ3hockRFOGVzUHgwWDJEWE12RURoR01mSmotMDRrUnFLMU8tbGFFQWVkOFpNRC1TdnE1UUl1SUw4eG9iSWpR?oc=5" target="_blank">EVAX|Evaxion Biotec…
Evaxion (EVAX) Holds Near $2.82 as Consolidation Range Persists - Negative Gamma - dars.gov.et
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNNmdkUk42UWQ0bXU1UjlkMGc3YlZpNkxFUnBHOEdpdzJlVnVYQ2V5ajE1S0VUc2FxaC1UNlNrTmZHbGpLR2d0bW9BTDVnQi11WDFEdHM3em51QnktV3B4QVNLYk00enFwSTF4Uk5zdmxoWURmM2dtaFhKcFl2R3phVlp0V0NUWVhZOXJjM3…
EVAX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9nbUgtMFl6MkV2ejJsN2dGNzZITW1ET3loYjlaYjIyRnNxa25RNEpyclFxWDEyNjJZTVNTYnpEdFVGT1B3WjNYckRBdTNIdUJLVnMtTTBGLWdQaDhXTmtJN08tTU5oWVlEZ0NUR0RzaWJlZklXXzdqSkZB?oc=5" target="_blank">EVA…
EVAX — Frequently Asked Questions
What is the current share price of EVAX?
As of 2026-08-05 17:25 PDT, EVAX trades at $2.98 on NASDAQ/NYSE. Its 52-week range is $2.59 to $11.01.
What is the market capitalisation of EVAX?
EVAX has a market capitalisation of $1.24B on NASDAQ/NYSE.
What is the P/E ratio of EVAX?
EVAX trades at a trailing price-to-earnings (P/E) ratio of -2.98. Its price-to-book (P/B) ratio is 72.86.
What is the return on equity (ROE) of EVAX?
EVAX has a return on equity (ROE) of -45.23%. Its return on capital employed (ROCE) is -38.23%.
Is EVAX a good stock to buy?
This page provides a data-driven analysis of EVAX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.